India’s pharmaceutical and medical technology sectors stand at a defining moment in their evolution. While the country has earned global recognition as a cost-efficient manufacturing hub, the next phase of growth must be firmly rooted in research-led, innovation-driven development. The Promotion of Research and Innovation in Pharma Med-Tech (PRIP) Scheme was conceived as a catalytic policy instrument to enable this transition. However, recent observations by the Parliamentary Standing Committee on Chemicals and Fertilisers highlight a widening gap between policy intent and on-ground execution.
Parliamentary Scrutiny and the Need for Urgent Course Correction
In its Fifth Report on the Demands for Grants (2024–25), the Parliamentary Standing Committee, chaired by Kirti Azad Jha, directed the Department of Pharmaceuticals (DoP) to urgently resolve the issues impeding the implementation of the PRIP scheme. The Committee expressed concern that despite approval by the Union Cabinet in July 2023, with a substantial financial outlay of ₹5,000 crore over five years, the scheme has made little tangible progress.
The Committee noted that during FY 2023–24, no funds were sought at the Budget Estimate stage, and although ₹1 crore was allocated at the Revised Estimate stage, actual expenditure remained nil. One of the principal reasons cited was the inability to engage a Project Management Agency (PMA), as the tender process failed to attract any valid bids. These procedural and administrative delays have effectively stalled a scheme that was designed to be transformative for the sector.
The Strategic Rationale of the PRIP Scheme
The PRIP scheme was envisioned as a cornerstone of India’s long-term innovation strategy in pharmaceuticals and Med-Tech. Its overarching objective is to shift the sector from a volume-driven, cost-based model to one characterised by intellectual property creation, high-value research, and technological leadership.
At its core, the scheme seeks to:
- Strengthen industry–academia collaboration in priority research areas
- Create world-class research infrastructure within the country
- Foster a culture of quality research and nurture India’s scientific talent pool
A key pillar of the scheme is the establishment of Centres of Excellence (CoEs) across the seven existing National Institute of Pharmaceutical Education and Research (NIPERs). These CoEs were intended to serve as hubs for advanced research, translational science, and skill development, ultimately generating a steady pipeline of globally competitive scientists and innovators.
Focus on High-Impact Priority Areas
To maximise strategic and economic impact, the PRIP scheme identified six priority domains critical to India’s future competitiveness and global health relevance:
1. New chemical and biological entities
2. Complex generics and biosimilars
3. Precision and personalised medicines
4. Medical devices and diagnostics
5. Orphan drugs for rare diseases
6. Drug development addressing antimicrobial resistance (AMR)
Targeted investment in these areas would enable the Indian pharmaceutical industry to leapfrog technologically, strengthen its global market position, and contribute meaningfully to addressing pressing and emerging medical challenges worldwide.
A Sound Three-Pillar Framework
From a policy design perspective, PRIP is anchored in a robust three-pronged strategy. The first pillar focuses on regulatory enablement, aimed at streamlining approvals, reducing bureaucratic friction, and accelerating regulatory timelines to create a research-friendly environment. The second pillar emphasises investment incentivisation, encouraging both public and private sector participation through a balanced mix of fiscal incentives, grants, and non-fiscal support measures. The third pillar centres on ecosystem development, with the objective of establishing a sustainable institutional framework that supports innovation, translational research, and long-term sectoral growth.
If implemented effectively, this integrated framework has the potential to create a virtuous cycle of innovation, investment, and talent development.
Why Timely Execution Is Critical
In an increasingly competitive global environment, where pharmaceutical innovation is closely linked to economic resilience and healthcare sovereignty, delays in execution carry significant costs. Effective implementation of the PRIP scheme would not only enhance India’s global standing but also generate high-quality employment, retain domestic scientific talent, and build enduring national research capabilities.
Conversely, prolonged implementation gaps risk eroding stakeholder confidence and diluting the transformative potential of one of India’s most ambitious pharma and Med-Tech policy initiatives.
From Policy Intent to Measurable Impact
The Parliamentary Committee’s directive should be viewed as a timely and constructive intervention rather than a mere procedural observation. The responsibility now rests squarely with the Department of Pharmaceuticals to demonstrate administrative agility, strategic clarity, and executional urgency. Swift finalisation of institutional mechanisms, timely deployment of funds, and deeper engagement with industry and academia will be essential to restoring momentum.
The PRIP scheme holds the promise to redefine India’s pharmaceutical and Med-Tech future. What is required now is decisive implementation in letter and spirit, ensuring that policy ambition translates into measurable innovation outcomes and positions India as a credible global leader in pharmaceutical and medical technology research.
